Tg Therapeutics (TGTX) Non-Current Deffered Revenue (2012 - 2026)

Tg Therapeutics' Non-Current Deffered Revenue history runs 15 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 4.02% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 4.02% increase from a year earlier, with the FY2025 full-year figure at $8.8 million, down 27.12% from the prior year.
• Non-Current Deffered Revenue slipped to $6.9 million in Q1 2026 per TGTX's latest filing, from $8.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $16.2 million in Q3 2024 and bottomed at $305000.0 in Q4 2022.
• The 5-year median for Non-Current Deffered Revenue is $3.2 million (2024), against an average of $4.8 million.
• Across the five-year window, Non-Current Deffered Revenue tumbled 83.41% in 2022 and jumped 1872.46% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $305000.0 in 2022, then soared by 1872.46% to $6.0 million in 2023, then surged by 100.88% to $12.1 million in 2024, then declined by 27.12% to $8.8 million in 2025, then decreased by 22.07% to $6.9 million in 2026.
• Per Business Quant, the three latest TGTX Non-Current Deffered Revenue figures stand at $6.9 million (Q1 2026), $8.8 million (Q4 2025), and $8.3 million (Q3 2025).